ANNX - MCAP CO - Annexon, Inc.

Annexon, Inc. (ANNX) specializes in developing classical complement inhibitors, focusing on the protection of cognitive functions and vision. The price action on GURU.Markets, where the indicator stands at 0.63, confirms the issuer's market position. The business relies on unique inhibitors for the therapy of neuropathies, and the high value of its assets is supported by patents for C1q protein blocking, which create a significant barrier to entry for competitors.

Defensive assets are selected based on their resilience to external shocks, and Annexon, Inc. (ANNX) meets this criterion through its international medical status and integration into US and EU clinics. The market value, which stands at 0.63, is calculated as the product of the share price and the number of issued securities. By analyzing the issuer's total market capitalization, an investor determines the company's current market weight. This metric allows for an assessment of whether the asset is overvalued relative to its fundamental value.